Wide access to potential molecular drug targets to treat pulmonary fibrosis is now possible, as researchers have mapped the complete set of…
Articles by Magdalena Kegel
A higher fat-free mass index — a measure that takes a person’s muscle mass into account — predicts better survival in patients with…
Bristol-Myers Squibb has acquired exclusive worldwide rights to Nitto Denko’s antifibrotic drug development efforts with siRNA molecules. In addition to…
Australian and German companies, AdAlta and  XL-protein, have entered into a collaboration to create a long-acting form of AdAlta’s AD-114, an…
An extract from an earthworm reduced inflammation and fibrosis in the lungs of mice exposed to silica, acting through known…
Mice that produce excessive amounts of an anticoagulant factor are somewhat protected against pulmonary fibrosis development, a finding that highlights…
Mesenchymal stem cells show considerable potential as a means of treating idiopathic pulmonary fibrosis (IPF), but numerous issues need to be resolved…
Patients with idiopathic pulmonary fibrosis (IPF) who demonstrate adequate lung volume still have the same rate of lung volume decline…
Esbriet (pirfenidone) is as safe a treatment for idiopathic pulmonary fibrosis (IPF) in the long-term as it is already known…
Physical inactivity and low blood-oxygen levels during periods of exercise predict poor survival in patients with idiopathic pulmonary fibrosis (IPF), according to researchers…